



POT/EP200 4 / 0 0 3 9 8 0


EPO4/3980

15. 04 2004



INVESTOR IN PEOPLE

BEST AVAILABLE COPY




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

29 January 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



The
**Patent
Office**

17APR03 E800948-2 D00524
P01/7700 0.00-0308854.9

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1.	Your reference	4-33172P1		
2.	Patent application number <i>(The Patent Office will fill in this part)</i>	0308854.9		16 APR 2003
3.	Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i>	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND 1725487005 SWITZERLAND		
	Patent ADP number <i>(if you know it)</i> If the applicant is a corporate body, give the country/state of its incorporation			
4.	Title of invention	Organic Compounds		
5.	Name of your agent <i>(if you have one)</i> "Address for service" in the United Kingdom to which all correspondence should be sent <i>(including the postcode)</i>	B.A. YORKE & CO. CHARTERED PATENT AGENTS COOMB HOUSE, 7 ST. JOHN'S ROAD ISLEWORTH MIDDLESEX TW7 6NH		
	Patents ADP number <i>(if you know it)</i>	1800001 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? <i>(Answer 'Yes' if:</i> a) <i>any applicant named in part 3 is not an</i> <i>inventor, or</i> b) <i>there is an inventor who is not named as</i> <i>an applicant, or</i> c) <i>any named applicant is a corporate</i> <i>body.</i> <i>(see note (d))</i>			
	Yes			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 9

Claim(s) 3

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

B.A. Yorke & Co.

16th April 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. S. Schnerr
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.


Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

The present invention relates to a novel process for the preparation of N-(N'-substituted glycy)-2-cyanopyrrolidines and a composition obtainable according to the novel process comprising predominantly N-(N'-substituted glycy)-2(S)-cyanopyrrolidine.

N-(N'-substituted glycy)-2-cyanopyrrolidines, especially those of formula I



wherein R is as defined below; in free form or in acid addition salt form; are valuable dipeptidyl peptidase-IV (DPP-IV) inhibitors which have been described in WO 98/19998, for example.


The conventional process for preparation of N-(N'-substituted glycy)-2-cyanopyrrolidines, especially those of formula I above, comprises reacting a halogen (preferably chlorine or bromine) substituted (2-cyanopyrrolidino)carbonylmethylene with an appropriate amine. Said substituted (2-cyanopyrrolidino)carbonylmethylene may be obtained by reacting a haloacetylhalide with L-prolinamide followed by a dehydration with trifluoroacetic anhydride. This process has significant drawbacks, especially when considering industrial production of N-(N'-substituted glycy)-2-cyanopyrrolidines, as both the 1-haloacetyl-2-cyanopyrrolidine intermediate and its direct precursor are classified as irritant. Furthermore the process needs aqueous work up at several steps resulting in potential waste problems and lower yields. It has also recently been reported an alternative synthesis based on solid phase chemistry which avoids free 1-haloacetyl-2-cyanopyrrolidine but which process is not suitable for scale-up according to its authors (N. Willand et al., Tetrahedron 58 (2002) 5741-5746). Thus, there exists a need for an improved process.

It has now been found that surprisingly the 1-haloacetyl-2-cyanopyrrolidine intermediate may be prepared in such a way that no isolation of said irritant compound is needed. Said compound may therefore be directly further reacted with the appropriate amine. In addition,

the new process allows to recycle all solvents and the only by-products are inorganic salts. The new process is characterised by a high overall yield and is suitable for industrial production.

Therefore, an object of the instant invention is the process for the preparation of a N-(N'-substituted glycyI)-2-cyanopyrrolidine comprising at least

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH or $O-C(=O)-CH_2X_3$


with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and

(d) recovering the resultant compound in free form or in acid addition salt form.

Specifically, an object of the instant invention is the process for the preparation of a compound of formula (I)




wherein R is

a) $R_1R_{1a}N(CH_2)_m$ - wherein

R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C_{1-4}) alkyl, (C_{1-4}) alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C_{1-4}) alkyl, (C_{1-4}) alkoxy or halogen;

R_{1a} is hydrogen or (C_{1-3}) alkyl; and

- m is 2 or 3;
- b) (C₃₋₁₂)cycloalkyl optionally monosubstituted in the 1-position with (C₁₋₃)hydroxyalkyl;
- c) R₂(CH₂)_n - wherein either
- R₂ is phenyl optionally mono- or independently di- or independently trisubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C₁₋₈)alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C₁₋₈)alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; cyclohexenyl; or optionally substituted adamantyl; and
- n is 1 to 3; or
- R₂ is phenoxy optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; and
- n is 2 or 3;
- d) (R₃)₂CH(CH₂)₂ - wherein each R₃ independently is phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;
- e) R₄(CH₂)_p - wherein R₄ is 2-oxopyrrolidinyl or (C₂₋₄)alkoxy and p is 2 to 4;
- f) isopropyl optionally monosubstituted in 1-position with (C₁₋₃)hydroxyalkyl; or
- g) R₅ wherein R₅ is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C₁₋₈)alkyl; adamantyl; or (C₁₋₈)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;
- in free form or in acid addition salt form
- comprising
- (a) reacting, in the presence of dimethylformamide, a compound of formula (V)



wherein, independently of each other, X₁ and X₃ are halogen; X₂ is halogen, OH or O-C(=O)-CH₂X₃

with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, preferably optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine, preferably a compound of formula (VI)



wherein R is as defined for formula (I) and

(d) recovering the resultant compound in free form or in acid addition salt form.

Reaction (a) is conveniently carried out under an inert atmosphere and in the presence of dimethylformamide and a further inert, organic solvent or a mixture of such solvents, preferably isopropyl acetate or ethyl acetate. The temperature preferably is from about 5° to about 45°C and most preferred from about 10° to about 35°C. Preferably a 2 to 20% molar excess of (V) is used. Preferably, no base is added. Preferred are compounds of formula (V) wherein both X_1 and X_2 are halogen, preferably chlorine or bromine, particularly preferred X_1 and X_2 are the same and most preferred X_1 and X_2 are both chlorine.

Reaction (b) is conveniently carried out under an inert atmosphere and in the presence of an inert, organic solvent, preferably a mixture of isopropyl acetate and dimethylformamide. The temperature preferably is from about 15° to about 45°C and most preferred from about 20° to about 35°C. Suitable dehydration agents are (haloalkylene)dialkylammonium halogenids, wherein the alkyl or alkylene is a, preferably straight, carbon chain of 1 to 4 carbon atoms, most preferred methyl or methylene, and halogen is chlor, brom or iod, most preferred chlor. Most preferred as a dehydration agent is (chloromethylene)dimethylammonium chloride. Preferably a 2 to 20% molar excess of the dehydration agent is used. Subsequently any excess of (chloromethylene)dimethylammonium chloride may be decomposed by the addition of a small amount of water.

Reaction (c) is conveniently carried out under an inert atmosphere whereby the resultant reaction product of (b) is added to a solution or suspension of the amine compound of formula (VI) in an inert, organic solvent, preferably 2-butanone, acetone, acetonitrile or dimethylformamide. The temperature preferably is from about 5° to about 60°C and most preferred from about 10° to about 35°C. Preferably a catalytic amount (for example 1 to 10%, preferably about 5%) of potassium iodide is used. The amine of formula (VI) is used in 5 to 35% molar excess, preferably in 10 to 25% molar excess. Conveniently the base, used in an amount of 2 to 10eq, preferably about 5.5eq, may be an alkali carbonate or NaOH, preferably Na_2CO_3 or K_2CO_3 and most preferred K_2CO_3 .

Recovery (d) conveniently comprises filtering the reaction mixture, removing the solvents under reduced pressure and recrystallising the crude product from a solvent. In a preferred embodiment, the solvent contains a N-base, for example 1,8-diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine, $N(C_4H_9)_3$, $N(C_2H_5)_3$, isobutylmorpholin or tetramethylpiperidin.

The compounds of formula (I) can exist in free form or in acid addition salt form. Salt forms may be recovered from the free form in known manner and vice-versa. Acid addition salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric, phosphoric, citric, lactic and acetic acid may also be utilized.

"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the latter are isopropyl and tert-butyl.

R preferably is a) or c) as defined above.

R_1 preferably is a pyridinyl or pyrimidinyl moiety optionally substituted as defined above. R_{1a} preferably is hydrogen. R_2 preferably is optionally substituted phenyl or adamantyl. R_3 preferably is unsubstituted phenyl. R_4 preferably is alkoxy as defined above. R_5 preferably is optionally substituted alkyl as defined above, m preferably is 2. n preferably is 1 or 2, especially 2. p preferably is 2 or 3, especially 3.

Pyridinyl preferably is pyridin-2-yl; it preferably is unsubstituted or monosubstituted, preferably in 5-position. Pyrimidinyl preferably is pyrimidin-2-yl. It preferably is unsubstituted or monosubstituted, preferably in 4-position. Preferred as substituents for pyridinyl and pyrimidinyl are halogen, cyano and nitro, especially cyano.

When it is substituted, phenyl preferably is monosubstituted; it preferably is substituted with halogen, preferably chlorine, or methoxy. It preferably is substituted in 2-, 4- and/or 5-position, especially in 4-position.

(C_{3-12}) cycloalkyl preferably is cyclopentyl or cyclohexyl. When it is substituted, it preferably is substituted with hydroxymethyl. (C_{2-4}) alkoxy preferably is of 1 or 2 carbon atoms, it especially is methoxy. (C_{1-3}) alkoxy preferably is of 3 carbon atoms, it especially is isopropoxy. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, especially

chlorine. (C₁₋₈)alkyl preferably is of 1 to 6, preferably 1 to 4 or 3 to 5, especially of 2 or 3 carbon atoms, or methyl. (C₁₋₄) alkyl preferably is methyl or ethyl, especially methyl. (C₁₋₃)hydroxyalkyl preferably is hydroxymethyl.

A [3.1.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[3.1.1]hept-2-yl optionally disubstituted in 6-position with methyl, or bicyclo[3.1.1]hept-3-yl optionally trisubstituted with one methyl in 2-position and two methyl groups in 6-position. A [2.2.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[2.2.1]hept-2-yl.

Naphthyl preferably is 1-naphthyl. Cyclohexene preferably is cyclohex-1-en-1-yl. Adamantyl preferably is unsubstituted or substituted by one or more, for example 2 substituents 1- or 2-adamantyl. Preferred substituents are selected from alkyl, -OR₁₀ or -NR₁₁R₁₂; where R₁₀, R₁₁ and R₁₂ are independently hydrogen, alkyl, C₁₋₈alkanoyl, carbamyl, or -CONR₁₃R₁₄; where R₁₃ and R₁₄ are independently alkyl, unsubstituted or substituted aryl and where one of R₁₃ and R₁₄ additionally is hydrogen or R₁₃ and R₁₄ together represent C₂₋₇alkylene.

A pyrrolidiny1 or piperidiny1 moiety optionally substituted as defined above preferably is pyrrolidin-3-yl or piperidin-4-yl. When it is substituted it preferably is N-substituted.

Very preferred are compounds of formula (I)


wherein

R is R₂(CH₂)_n- and R₂ is substituted adamantyl; and


n is 0, 1, 2 or 3; in free form or in acid addition salt form;

A preferred group is one of above compounds of formula (I) wherein the substituent on the adamantyl is bonded on a bridgehead.

Especially preferred compounds are compounds of formula



or



wherein R' is hydroxy, C₁₋₇alkoxy, C₁₋₈alkanoyloxy, or R'''R''''N-C(O)O-, where R''' and R'''' independently are C₁₋₇alkyl or phenyl which is unsubstituted or substituted by a substituent selected from C₁₋₇alkyl, C₁₋₇alkoxy, halogen and trifluormethyl and where R''' additionally is hydrogen; or R''' and R'''' together are C₃₋₆alkylene; and R'' is hydrogen; or R' and R'' independently are C₁₋₇alkyl; in free form or in acid addition salt form.

Very particularly preferred is the compound of formula (IA) wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

The compounds of formula (I) exist in the form of optically active isomers or stereoisomers and can be separated and recovered by conventional techniques, however the above described process is capable of yielding compounds of formula (I) with a high (at least 95%) enantiomeric purity of the N-(N'-substituted glycy)-2(S)-cyanopyrrolidine.

Therefore, a further object of the instant invention is a composition of N-(N'-substituted glycy)-2(S)-cyanopyrrolidine and N-(N'-substituted glycy)-2(R)-cyanopyrrolidine, obtainable according to the above described process, whereby 95% to 99,9% is N-(N'-substituted glycy)-2(S)-cyanopyrrolidine and 5% to 0,1% is N-(N'-substituted glycy)-2(R)-cyanopyrrolidine, especially whereby 98% to 99,9% is N-(N'-substituted glycy)-2(S)-cyanopyrrolidine and 2% to 0,1% is N-(N'-substituted glycy)-2(R)-cyanopyrrolidine.

Preferred N-(N'-substituted glycy)-2(S)-cyanopyrrolidines are those described as preferred compounds in the above process.

Examples

Example 1)

Preparation of Pyrrolidine, 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-, (S):

Step (a)

A 1500 ml reactor, equipped with a mechanical stirrer, is charged with 212 g isopropyl-acetate and 19.8 g dimethylformamide. The reactor is inertized. At about IT (internal temperature) 15 °C, 125 g chloroacetylchloride is added within 15 min., after complete addition the IT is adjusted to about 15 °C, and a solution of 110 g L-prolinamide in 304 g dimethylformamide is added within 1 h. The addition funnel is rinsed with 18 g isopropyl-acetate. The reaction mixture is warmed to about IT 35 °C for 1.5 h.

Step (b)

After cooling to about 15 °C 142 g (chloromethylene)dimethylamonium chloride is added in portions. The reaction mixture is stirred for 1 h at about IT 25 °C. At IT max. 25 °C 4.4 g water is added.

Step (c)

A 4.5 l reactor, equipped with a mechanical stirrer, is charged with 733 g of potassium carbonate, 194 g 3-hydroxyaminoadamantane, 8.0 g potassium iodide and 880 g 2-butanone. The suspension is heated to about 35 °C. At this temperature 937 g solution of step b) (crude (S)-1-chloroacetyl-pyrrolidine-2-carbonitrile) is added within 1.5 h. The addition funnel is rinsed with 20 g 2-butanone. After stirring for an additional 1 h, the suspension is warmed to about IT 70 °C for 30 min. The warm suspension is filtered and the filter cake is rinsed three times with warm 331 g 2-butanone. The filtrate is concentrated at about JT (jacket temperature) 60 °C under reduced pressure (about 20 mbar).

Step (d)

At about JT 60 °C 8.8 g 1,8-diazabicyclo[5.4.0]undec-7-ene and 44 g isopropanol is added and stirred for 30 min. at IT about 60 °C. The resulting suspension is cooled to about IT 40 °C and at JT 40 °C 814 g t-butylmethylether is added. The suspension is cooled to about IT 20 °C and stirred for at least 2 h at this temperature, then cooled to about -10°C - 0 °C, stirred for 1 h and filtered. The filtration "cake" is washed twice with 168 g of a cold (about -10 °C) 1:1 (v:v) mixture of isopropanol and t-butylmethylether. The crude product (247 g) is dried under reduced pressure at about JT 55 °C.


Example 2:**Purification of Pyrrolidine, 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-, (S):**

A 750 ml reactor, equipped with a mechanical stirrer, is charged with 199 g of crude 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile, 800 g 2-butanone. The mixture is heated to reflux (JT 95 °C) and stirred for 15 min. The mixture is filtered into a warm (JT 75 °C) reactor, the filter cake is washed with 80 g 2-butanone. The IT is adjusted to 70 °C and 0.18 g (1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile) suspended in 1.6 g 2-butanone are added. The resulting suspension is stirred for 30 min., cooled to IT 50 °C within 2 h then to 30 °C within 1 h finally to 0 °C within 1 h and stirred for 1 additional h. After this the suspension is filtered and the crude product is washed twice with a cold (0°C) mixture of 60.4 g 2-butanone and 55.5 g t-butyl methyl ether. The product is dried under reduced pressure at about JT 55 °C. The melting point is 148°C.

Claims:

1. Process for the preparation of a N-(N'-substituted glycyI)-2-cyanopyrrolidine comprising at least

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH or $O-C(=O)-CH_2X_3$


with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and

(d) recovering the resultant compound in free form or in acid addition salt form.

2. A process according to claim 1 wherein the N-(N'-substituted glycyI)-2-cyanopyrrolidine is a compound of formula (I)



wherein R is

a) $R_1R_{1a}N(CH_2)_m$ - wherein

R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C_{1-4}) alkyl, (C_{1-4}) alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C_{1-4}) alkyl, (C_{1-4}) alkoxy or halogen;

R_{1a} is hydrogen or (C_{1-8}) alkyl; and

m is 2 or 3;

b) (C₃₋₁₂)cycloalkyl optionally monosubstituted in the 1-position with (C₁₋₃)hydroxyalkyl;

c) R₂(CH₂)_n - wherein either

R₂ is phenyl optionally mono- or independently di- or independently trisubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C₁₋₈)alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C₁₋₈)alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; cyclohexenyl; or optionally substituted adamantyl; and

n is 1 to 3; or

R₂ is phenoxy optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; and

n is 2 or 3;

d) (R₃)₂CH(CH₂)₂- wherein each R₃ independently is phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;

e) R₄(CH₂)_p - wherein R₄ is 2-oxopyrrolidinyl or (C₂₋₄)alkoxy and p is 2 to 4;

f) isopropyl optionally monosubstituted in 1-position with (C₁₋₃)hydroxyalkyl; or

g) R₅ wherein R₅ is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C₁₋₈)alkyl; adamantyl; or (C₁₋₈)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;

in free form or in acid addition salt form.

3. A process according to claim 1 or 2 wherein the dihydration agent of step (b) is a (haloalkylene)dialkylammonium halogenid.

4. A process according to claim 1 or 2 wherein the dihydration agent of step (b) is (chloromethylene)dimethylammonium chloride.


5. A process according to claim 2 wherein the amine of step (c) is a compound of formula (VI)



wherein R is as defined for formula (I) in claim 2.

6. A process according to claim 2 comprising

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



wherein X_1 is halogen; X_2 is halogen, OH or $O-C(=O)-CH_2X$ with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with (chloromethylene)dimethylammonium chloride, followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with a compound of formula (VI)




wherein R is as defined for formula (I) and

(d) recovering the resultant compound in free form or in acid addition salt form.

7. A composition of N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 1 or 2, whereby 95% to 99,9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 5% to 0,1% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, especially whereby 98% to 99,9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 2% to 0,1% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine.

8. A composition according to claim 7, whereby the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is a compound of the formula




wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Abstract:

The present invention relates to a process for the preparation of a N-(N'-substituted glycy)-2-cyanopyrrolidine comprising at least

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



wherein, independently of each other, X₁ and X₃ are halogen; X₂ is halogen, OH or O-C(=O)-CH₂X₃

with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and

(d) recovering the resultant compound in free form or in acid addition salt form.

EP 04 3980



CAU

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.